{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T15:14:54Z","timestamp":1781968494889,"version":"3.54.5"},"reference-count":8,"publisher":"PAGEPress Publications","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatol Reports"],"abstract":"<jats:p>We present a case of a 15-year-old male diagnosed with multiple autoimmune conditions, including atopic dermatitis (AD), Crohn\u2019s disease (CD), alopecia areata (AA), and eosinophilic gastroenteropathy. After failure of previous therapies, the patient was successfully treated with upadacitinib, a Janus Kinase 1 (JAK-1) inhibitor. Significant improvement in skin and gastrointestinal symptoms, as well as hair regrowth, was observed following 16 weeks of treatment. This case highlights the therapeutic potential of JAK inhibitors like upadacitinib in managing complex autoimmune disorders that share common pathogenic pathways.<\/jats:p>","DOI":"10.4081\/dr.2026.10165","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T08:19:26Z","timestamp":1767946766000},"source":"Crossref","is-referenced-by-count":2,"title":["Successful treatment with upadacitinib in concurrent atopic dermatitis, Crohn\u2019s disease, alopecia areata, and eosinophilic gastropathy in a pediatric patient"],"prefix":"10.4081","author":[{"given":"Edoardo","family":"Mortato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovico Maria","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Aloi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaldo","family":"Cioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Matteini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Fico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lambiase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruslana","family":"Gaeta Shumak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Campione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Diluvio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2549","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"35334","unstructured":"1. Padda IS, Bhatt R, Patel P, Parmar M. Upadacitinib. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Available from:"},{"key":"35335","unstructured":"www.ncbi.nlm.nih.gov\/books\/NBK572088\/#:~:text=Mechanism%20of%20Action (accessed on 4 July 2024)."},{"key":"35336","doi-asserted-by":"crossref","unstructured":"2. Dignass A, Esters P, Flauaus C. Upadacitinib in Crohn\u2019s disease. Expert Opin Pharmacother 2024;25:359-70.","DOI":"10.1080\/14656566.2024.2333964"},{"key":"35337","doi-asserted-by":"crossref","unstructured":"3. Novielli D, Foti C, Principi M, et al. Upadacitinib in concurrent Crohn\u2019s disease, atopic dermatitis and alopecia areata: A case report. J Eur Acad Dermatol Venereol 2024;38:e8-10.","DOI":"10.1111\/jdv.19377"},{"key":"35338","doi-asserted-by":"crossref","unstructured":"4. Kageyama R, Ito T, Hanai S, et al. Immunological properties of atopic dermatitis-associated alopecia areata. Int J Mol Sci 2021;22:2618.","DOI":"10.3390\/ijms22052618"},{"key":"35339","doi-asserted-by":"crossref","unstructured":"5. Dudek P, Fabisiak A, Zatorski H, et al. Efficacy, safety and future perspectives of JAK inhibitors in the IBD treatment. J Clin Med 2021;10:5660.","DOI":"10.3390\/jcm10235660"},{"key":"35340","doi-asserted-by":"crossref","unstructured":"6. Maghfour J, Olson J, Conic RRZ, Mesinkovska NA. The Association between Alopecia and Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Dermatology 2021;237:658-72.","DOI":"10.1159\/000512747"},{"key":"35341","doi-asserted-by":"crossref","unstructured":"7. Fu J, Sia T, Solecki R, et al. Clinical and histologic remission achieved with upadacitinib in a patient with refractory eosinophilic gastritis and duodenitis. J Allergy Clin Immunol Pract 2024;12:1649-51.","DOI":"10.1016\/j.jaip.2024.02.031"}],"container-title":["Dermatology Reports"],"original-title":[],"link":[{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/download\/10165\/9839","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/download\/10165\/9839","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T08:19:28Z","timestamp":1767946768000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/view\/10165"}},"subtitle":["Use of upadacitinib in pediatric comorbidities"],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":8,"URL":"https:\/\/doi.org\/10.4081\/dr.2026.10165","relation":{},"ISSN":["2036-7406","2036-7392"],"issn-type":[{"value":"2036-7406","type":"electronic"},{"value":"2036-7392","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,9]]}}}